Genix Pharmaceuticals Issues Clarification to Previously Announced Private Placement Terms

Core Viewpoint - Genix Pharmaceuticals Corporation issued a clarification regarding the terms of its recently closed non-brokered private placement, correcting the issue price of the units from $0.10 to $0.05 per unit [1][2]. Summary by Sections Private Placement Details - The company issued 2,000,000 units at a corrected price of $0.05 per unit, resulting in total gross proceeds of $100,000 [3]. - Each unit consists of one common share and one transferable common share purchase warrant, with each warrant allowing the holder to acquire one additional share at a price of $0.10 for two years, expiring on September 4, 2027 [3]. Company Overview - Genix Pharmaceuticals is a Canadian company focused on innovative ophthalmic drugs, including research, development, manufacturing, licensing, and sales of prescription and OTC ophthalmological products [5]. - The company aims to meet the growing needs of consumers, particularly the aging baby boomer population, and has several products awaiting Health Canada approval [5].